AbbVie Data Show Skyrizi Tops IL-17 Competitors In Skin Clearance

21 Mar 2023

Skyrizi showed better skin-clearance results than Cosentyx or Taltz in a 52-week study of patients who had suboptimal results on the latter two drugs.

AbbVie Building — AbbVie's head-to-head psoriasis data showed Skyrizi bests the IL-17 class • Source: Shutterstock

Perhaps bolstering the already strong commercial presence for its IL-23 inhibitor and Humira successor Skyrizi, AbbVie Inc. unveiled data during the American Academy of Dermatology meeting that took place 17-21 March showing that the drug improves skin clearance in patients who switched over from IL-17-targeting therapies Cosentyx and Taltz following at least six months of treatment with suboptimal results.

Skyrizi (risankizumab), which the US Food and Drug Administration approved in April 2019 to treat adults with moderate-to-severe psoriasis, is...